Table 5 Univariate analyses of the PFS in EOC compared with clinicopathological and genomic characteristics and CD47

CD47 (high vs. low)

0.002

4.449 (1.698–11.924)

PD-L1 (positive vs. negative)

0.105

0.445 (0.167–1.183)

FIGO stage (I + II vs. III + IV)

0.013

3.863 (1.333–11.194)

Preoperative serum CA125 (≥ 500 U/mL vs. < 500 U/mL)

0.015

2.573 (1.198–5.525)

Preoperative serum HE4 (increased vs. normal)

0.466

1.451 (0.533–3.949)

Multidisciplinary surgeries (yes vs.no)

0.006

3.173 (1.386–7.261)

Presence of ascites (yes vs.no)

0.135

2.242 (0.779–6.453)

Volume of ascites (≥ 1000 ml vs. < 1000 ml)

0.037

2.201 (1.049–4.620)

Lymph-node metastasis (positive vs. negative)

0.005

3.110 (1.404–6.890)

Ki-67 index (positive vs. negative)

0.129

1.800 (0.843–3.845)

Residual disease (optimal vs. suboptimal)

0.544

1.302 (0.555–3.057)

BRCA mutation status (pathogenic mutation vs. wild type)

0.091

0.434 (0.165–1.142)

HRD status^a (positive vs. negative)

0.074

0.429 (0.169–1.087)

TP53 mutation status (pathogenic mutation vs. wild type)

0.877

1.065 (0.476–2.383)